HCA Healthcare’s Sarah Cannon Cancer Institute Implements New Outpatient Model for CAR T-cell Therapy
23 February 2024 - 8:30AM
Business Wire
HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading
healthcare providers, today announced that the Sarah Cannon Cancer
Institute (SCCI) of HCA Healthcare has successfully established an
integrated management process that safely transitioned more than
75% of HCA Healthcare’s CAR T-cell therapy patients into an
outpatient setting for monitoring. The program model resulted in
more than 1,200 hospital bed days saved for the first 100 patients
of the program compared to historical results, and approximately
20% of patients avoided hospitalization altogether.
Piloted at four Sarah Cannon Transplant and Cellular Therapy
Network (SCTCTN) sites and using new technology for at-home patient
monitoring, trained outpatient clinical teams, including nurses,
clinical pharmacists, advanced practice professionals, social
workers and case managers, have created a model to help reduce the
time patients spend in the hospital after treatment during the
typical two-week monitoring period.
“Patients heal better outside the hospital if they can get these
complicated therapies, which carry risk for significant
complications, safely in the outpatient setting,” said Dr. Navneet
Majhail, physician-in-chief of blood cancers, Sarah Cannon
Transplant & Cellular Therapy Network. “We have leveraged
technology and developed clinical pathways to care for patients
receiving CAR T-cell therapies. Our clinical teams have
accomplished this by standardizing care across a network of several
cell therapy programs. In addition to patient benefits, their work
has helped us better anticipate and meet the increasing demand for
cell therapies as we continue to innovate our care delivery models
to enhance timely access for these important treatments.”
Chimeric antigen receptor T-cell therapy, also known as CAR
T-cell therapy, is an immunotherapy designed to program a patient’s
immune system to recognize and fight cancer. During the CAR T-cell
treatment process, T-cells are drawn from a patient’s blood and
genetically modified to recognize the patient’s cancer cells when
reinfused. Because these oncology patients require intensive,
specialized and time-sensitive care, they are closely monitored for
any complications and have historically required inpatient
hospitalization for up to two weeks post infusion.
In February 2023, SCTCTN, through a collaboration with Best Buy
Health, launched the initiative to safely transition a substantial
portion of CAR T-cell therapy monitoring into patients’ homes. Best
Buy Health’s remote patient monitoring platform, Current Health,
tailored for CAR T-cell therapy patients, collects continuous vital
sign data and monitors symptoms through integrated wearable
devices. A dedicated team triages, manages and escalates patients'
needs to SCTCTN teams locally, including registered nurses, using
the Current Health platform to provide 24/7 monitoring.
Colleagues from SCCI will be presenting three research abstracts
on their experience with this initiative during this year’s
Transplantation & Cellular Therapy Tandem Meetings of ASTCT and
CIBMTR, February 21-24, in San Antonio, Texas. HCA Healthcare plans
to expand this model of care to additional SCTCTN sites over the
next year seeking to further improve patient and caregiver
experiences nationwide.
HCA Healthcare is one of the nation’s largest health system
research site networks with more than 43 million patient encounters
annually. The SCTCTN is one of the nation’s largest providers of
CAR T-cell therapies with more than 300 patients treated in 2023.
Patients are treated across multiple cell therapy programs using
standardized eligibility criteria, clinical pathways, and
guidelines for supportive care and toxicity management.
About HCA Healthcare
Nashville-based HCA Healthcare is one of the nation’s leading
providers of healthcare services comprising 186 hospitals and
approximately 2,400 ambulatory sites of care, including surgery
centers, freestanding ERs, urgent care centers, and physician
clinics, in 20 states and the United Kingdom. With its founding in
1968, HCA Healthcare created a new model for hospital care in the
United States, using combined resources to strengthen hospitals,
deliver patient-focused care and improve the practice of medicine.
HCA Healthcare has conducted a number of clinical studies,
including one that demonstrated that full-term delivery is
healthier than early elective delivery of babies and another that
identified a clinical protocol that can reduce bloodstream
infections in ICU patients by 44%. HCA Healthcare is a learning
health system that uses its more than 43 million annual patient
encounters to advance science, improve patient care and save
lives.
About Sarah Cannon Cancer Institute
The Sarah Cannon Cancer Institute (SCCI) offers integrated
cancer services with convenient access to leading therapies for
those facing cancer in communities across the United States and the
United Kingdom. SCCI partners with facilities to help ensure the
delivery of high-quality offerings for our patients, referrers, and
physicians is accessible and affordable. SSCI strives to be a
world-class cancer center closer to home with its suburban and
community-based providers. They provide high quality care through
HCA Healthcare’s resources such as access to proprietary software
to read pathology reports for early identification.
Sarah Cannon’s Transplant and Cellular Therapy Network is the
largest provider of hematological cancer treatment in the United
States and offers adult and pediatric patients convenient and
community-based access to treatments for blood cancer and blood and
immune-related disorders, including hematopoietic cell
transplantation and cellular therapy.
All references to “Company,” “HCA” and “HCA
Healthcare” as used throughout this document refer to HCA
Healthcare, Inc. and its affiliates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240222455650/en/
INVESTOR CONTACT: Frank Morgan 615-344-2688 MEDIA
CONTACT: Harlow Sumerford 615-344-1851
HCA Healthcare (NYSE:HCA)
Historical Stock Chart
From Apr 2024 to May 2024
HCA Healthcare (NYSE:HCA)
Historical Stock Chart
From May 2023 to May 2024